@article {77, title = {Data from: Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images}, year = {2017}, abstract = {

Background and Purpose: In this study we investigated the interchangeability of planning CT and cone-beam CT (CBCT) extracted radiomic features. Furthermore, this study validates a previously\ described CT based prognostic radiomic signature for non-small cell lung cancer (NSCLC) patients using CBCT based features.

Material and Methods: One internal dataset of 132 and two external datasets of 62 and 94 stage I-IV NSCLC patients were included in this study. Interchangeability was assessed by performing a linear regression on CT and CBCT extracted features. A two-step correction was applied prior to model validation of a previously published radiomic signature.

Results: 13.3\% (149 out of 1119) of the radiomic features, including all features of the previously published radiomic signature, showed an R2 above 0.85 between intermodal imaging techniques. For the radiomic signature, Kaplan-Meier curves were significantly different between groups with high and low prognostic value for both modalities. Harrell{\textquoteright}s concordance index was 0.69 for CT and 0.66 for CBCT models for dataset 1.

Conclusions: The results show that a subset of radiomic features extracted from CT and CBCT images are interchangeable using simple linear regression. Moreover, a previously developed radiomics signature has prognostic value for overall survival in three CBCT cohorts, showing the potential of CBCT radiomics to be used as prognostic imaging biomarker.

Kaplan-Meier curves for pCT and CBCT. Kaplan-Meier curves are based on model predictions of the radiomic signature.

}, keywords = {computed tomography, cone-beam CT, non-small cell lung cancer, Radiomics, survival prediction}, doi = {10.17195/candat.2017.02.1}, author = {Janita van Timmeren and Ralph T.H. Leijenaar and Wouter van Elmpt and Bart Reymen and Cary Oberije and Ren{\'e} Monshouwer and Johan Bussink and Carsten Brink and Olfred Hansen and Philippe Lambin} } @article {72, title = {Data from: Nitroglycerin in non-small cell lung cancer: does it impact tumor hypoxia and tumor perfusion? A window-of-opportunity clinical trial.}, year = {2016}, abstract = {

Despite preclinical evidence that nitric oxide (NO) donors influence both tumor perfusion and hypoxia, in clinical trials nitroglycerin has not been shown to improve the treatment results of all patients with non-small cell lung cancer (NSCLC). Biomarkers are therefore needed to select patients for treatment with NO donors. In this window-of-opportunity study we demonstrate the effect of nitroglycerin on hypoxia in patients using repeated hypoxia PET-imaging: we observed a reduction of hypoxia - quantified by uptake of PET tracer HX4- of varying magnitude upon application of a nitroglycerin patch in approximately two thirds of patients with hypoxic loco-regional disease.

In a quarter of patients with baseline hypoxia, the tumor and nodes become normoxic after treatment with nitroglycerin. Furthermore, through dynamic contrast enhanced CT-scans (DCE-CT) we demonstrated that this effect on hypoxic tracer uptake is negatively correlated with tumor perfusion in hypoxic tumors.

Using in vitro experiments we show that the metabolism of 2-nitroimidazoles is not influenced by nitroglycerin itself and furthermore that nitroglycerin does not inhibit mitochondrial respiration at human achievable concentrations. Therefore, 2-nitroimidazole based imaging biomarkers can be used to evaluate the nitroglycerin treatment efficacy in an individual patient.\ 

The current results do support the hypothesis that hypoxia scans and/or DCE-CT scans could form a tool to select patients for a nitroglycerin patch adjuvant to anti-cancer treatment (radiotherapy, chemotherapy, targeted agents or immunotherapy) to increase drug uptake and/or to decrease hypoxia.

An animation summarizing our results is available at https://youtu.be/udJSBYaRv9w.

Figure 1. Uptake of HX4 before and after nitoglycerin administration

A. Images of a HX4 PET/CT scan before and after nitroglycerin administration of the same patient.
B. Evolution of high-uptake fraction (HF) of HX4 after application of nitroglycerin patch in baseline hypoxic lesions. Blue = decline \> CR of HX4 (17\%), grey = stable: change \< CR.

Note: dataset was updated 2017-11-24
}, doi = {10.17195/candat.2016.07.2}, author = {Bart Reymen and Marike W. van Gisbergen and Aniek J.G. Even and Catharina M.L. Zegers and Cary Oberije and Felix Mottaghy and Marco Das and Ala Yaromina and Wouter van Elmpt and Dirk De Ruysscher and Ludwig Dubois and Philippe Lambin} } Error | CancerData.org

Error

The website encountered an unexpected error. Please try again later.